AACR and MPM announce three grants to support transformative cancer research
(American Association for Cancer Research) Three grants for research that could transform cancer therapies have been awarded by the AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants Program, an innovative partnership between the American Association for Cancer Research (AACR) and the UBS Oncology Impact Fund (OIF) managed by MPM Capital. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 21, 2021 Category: International Medicine & Public Health Source Type: news

Gold nanoparticles more stable by putting rings on them
(Hokkaido University) Hokkaido University scientists have found a way to prevent gold nanoparticles from clumping, which could help towards their use as an anti-cancer therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 21, 2021 Category: Cancer & Oncology Source Type: news

Synthetic biomaterial guides cancer therapy to hidden tumors
Advance opens up new possibilities for CAR T-cell therapy to treat a variety of cancers (Source: UCSF School of Pharmacy News)
Source: UCSF School of Pharmacy News - January 20, 2021 Category: Universities & Medical Training Source Type: news

Ultra-small nanomedicines which stably deliver oligonucleotides to refractory cancers
(Innovation Center of NanoMedicine) Ultra-small nanomedicines with a size of ca. 18 nm were fabricated by dynamic ion-pairing between Y-shaped block copolymers and oligonucleotide drugs. Chemically modified and double-stranded oligonucleotides dramatically enhanced the stability of the ultra-small nanomedicines in the bloodstream. The size allows for high permeability in cancer tissues by slipping through the cracks in tumor vasculatures and stromal tissues. Clinical trials and preclinical studies using the developed ultra-small nanomedicines are proceeding for refractory cancer therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 19, 2021 Category: Cancer & Oncology Source Type: news

Prelude, Onconova plan multimillion-dollar stock sales
Two Philadelphia-area biopharmaceutical companies focused on developing cancer therapies expect to raise a total of nearly $160 million from stock offerings Monday. The majority of the funds are expected to be raised by Prelude Therapeutics (NASDAQ: PRLD), a precision oncology company based in Wilmington. Prelude is selling 2.2 million shares of its voting common stock and 292,000 shares of its non-voting common stock, each at a public offering price of $60 p er share. The gross proceeds from the… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 11, 2021 Category: Pharmaceuticals Authors: John George Source Type: news

AI Drug Discovery Startup Valo Raises $190 Million And Unveils Cancer Therapy Programs
The Boston-based company aims to accelerate the drug discovery process for cancer therapies that are both more effective and less toxic. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 11, 2021 Category: Pharmaceuticals Authors: Alex Knapp, Forbes Staff Tags: Science /science Innovation /innovation Healthcare /healthcare AI /ai Editors' Pick editors-pick technology alexknappblog Source Type: news

Theolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies
OXFORD, England, Jan. 7, 2021 -- (Healthcare Sales & Marketing Network) -- Theolytics, a UK biotech harnessing viruses to combat cancer, today announced the closing of a US $6.8 million (UK £5 million) Series A round. The round was co-led by Epidare... Biopharmaceuticals, Oncology, Venture Capital Theolytics, oncolytic virus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 7, 2021 Category: Pharmaceuticals Source Type: news

Loss of anti-tumor protein may cause resistance to certain cancer therapies
(Penn State) The absence of a protein that works to prevent tumor formation may explain why some patients are resistant to a common cancer therapy, according to Penn State College of Medicine researchers. They said that testing cancers for the presence of this protein may help clinicians identify patients who may be resistant to or relapse when treated with the therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 21, 2020 Category: Cancer & Oncology Source Type: news

Karyopharm Announces FDA Approval of Xpovio (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
NEWTON, Mass., Dec. 18, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial stage pharmaceutical company pioneering novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 18, 2020 Category: Drugs & Pharmacology Source Type: news

Palliative care improves quality of life for patients with advanced blood cancer
(Massachusetts General Hospital) A first-of-its-kind intervention integrating palliative care early in the course of cancer therapy for patients with advanced acute myeloid leukemia (AML), a highly aggressive cancer of the blood and bone marrow, resulted in substantial improvements in patients' quality of life, mood and end-of-life care, a team of investigators has found. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 17, 2020 Category: Cancer & Oncology Source Type: news

TRIUMF enters collaboration with fusion pharmaceuticals to boost production of actinium-225
(PR Associates) TRIUMF, Canada's particle accelerator centre, today announced it has entered into a collaboration agreement with Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Under the agreement, Fusion will provide a financial investment enabling TRIUMF to upgrade its actinium-225 production infrastructure, and in return will receive preferred access to actinium-225, a rare medical isotope that shows great promise in new, cutting-edge cancer therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 16, 2020 Category: Cancer & Oncology Source Type: news

Report: More than 1,300 medicines and vaccines in development to help fight cancer
Over the last 30 years, significant progress has been made in the fight against cancer. Researchers have expanded their understanding of how cancer develops and how to target medicines for specific cancer types. Since peaking in 1991, the death rate associated with cancerdeclined by 29%, which translates to 2.9 million fewer cancer deaths. The most recent data shows that between 2016 and 2017 alone, cancer death ratesdeclined by 2.2%, the largest single-year drop ever recorded. Despite the challenges imposed by the COVID-19 pandemic, this momentum continues with biopharmaceutical companies focusing on research and dev...
Source: The Catalyst - December 15, 2020 Category: Pharmaceuticals Tags: Medicines in Development Cancer New Era of Medicine & D Focus Source Type: news

EMA Panel Endorses Approval of Five New Cancer Drugs EMA Panel Endorses Approval of Five New Cancer Drugs
The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended marketing authorization or has given a positive opinion regarding several cancer therapies.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Novel genomic tools increase the accuracy of breast cancer risk assessment
(University of Helsinki) Findings from the FinnGen study encompassing 120,000 women indicate that inherited breast cancer risk should be assessed in an increasingly comprehensive manner. Currently, only individual gene mutations are taken into consideration in breast cancer therapy and prevention. The study demonstrates that more extensive genomic data can be used to identify women who are at high risk of breast cancer with considerably greater accuracy. Such knowledge can especially improve risk assessment among the close relatives of breast cancer patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 14, 2020 Category: International Medicine & Public Health Source Type: news

How AI could make therapeutic decision-making for breast cancer more accurate, affordable
(Salesforce) Deep learning-enabled breast cancer technology could make breast cancer therapy decisions more accurate, affordable and accessible. For newly diagnosed breast cancer, estrogen receptor status (ERS) is a key molecular marker used for prognosis and treatment decisions. This is an expensive, time-consuming process. Here we show that machine learning can determine molecular marker status. Our approach could augment clinicians' capabilities in cancer prognosis and theragnosis by harnessing biological signals imperceptible to the human eye. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2020 Category: International Medicine & Public Health Source Type: news

Despite COVID-19 pandemic first patient undergoes new personalized immunotherapy
(University of California - San Diego) Bernard Thurman was referred to a personalized cancer therapy trial at Moores Cancer Center at UC San Diego Health, a collaboration with the La Jolla Institute for Immunology, the trial employs a patient's immune cells -- specifically tumor infiltrating lymphocytes (TIL) -- to destroy cancer cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2020 Category: Cancer & Oncology Source Type: news

Freiburg researcher Barbara Di Ventura receives two million-euro ERC Consolidator Grant
(University of Freiburg) The Freiburg engineer and biologist Prof. Dr. Barbara Di Ventura receives a Consolidator Grant from the European Research Council (ERC), one of the most prestigious prizes for European researchers, for her project " InCanTeSiMo - Intelligent cancer therapy with synthetic biology methods " . (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 9, 2020 Category: Cancer & Oncology Source Type: news

Potential cancer therapy may boost immune response
(Cedars-Sinai Medical Center) A new approach to cancer therapy shows potential to transform the commonly used chemotherapy drug gemcitabine into a drug that kills cancer cells in a specialized way, activating immune cells to fight the cancer, according to a study led by Cedars-Sinai Cancer investigators. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 7, 2020 Category: Cancer & Oncology Source Type: news

Milwaukee's Eversana strikes deal to commercialize breast cancer therapy that's nearing FDA go-ahead
The agency's decision is expected to drop Dec. 18. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 3, 2020 Category: American Health Authors: Sara Gilgore Source Type: news

Crowdsourcing for Cancer Therapy Favors Advantaged Crowdsourcing for Cancer Therapy Favors Advantaged
Cancer crowdfunding disproportionately benefits those in areas of high socioeconomic status and those with internet literacy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 3, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New map provides scientists with head start on how to destroy cancer-related enzymes
(Dana-Farber Cancer Institute) In a new paper in the journal Cell, investigators at Dana-Farber Cancer Institute provide a guide to approximately 200 such kinases, the first comprehensive map for scientists working in a field expected to have a major impact on cancer treatment. The map, publicly available online, will assist researchers in designing molecules that target specific kinases for destruction. Such molecules could serve as the templates for drugs more effective than many of today's targeted cancer therapies (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 3, 2020 Category: Cancer & Oncology Source Type: news

Combination therapy might improve outcomes in treatment-resistant liver cancer
(Massachusetts General Hospital) A combination cancer therapy that is effective against treatment-resistant hepatocellular carcinoma (HCC) by inhibiting tumor growth and increasing survival has been identified by researchers at Massachusetts General Hospital. The dual therapy -- which combines the multikinase inhibitor drug regorafenib to " reprogram " the tumor immune microenvironment, and programmed cell death 1 antibodies to stimulate anti-tumor immunity -- improved survival in mouse models of HCC beyond what each therapy could have achieved alone. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 30, 2020 Category: Cancer & Oncology Source Type: news

Surrey's new hybrid X-ray detector goes toe-to-toe with state-of-the-art rivals
(University of Surrey) A new hybrid X-ray detector developed by the University of Surrey outperforms commercial devices - and could lead to more accurate cancer therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 26, 2020 Category: Cancer & Oncology Source Type: news

Survival protein may prevent collateral damage during cancer therapy
(Walter and Eliza Hall Institute) Australian researchers have identified a protein that could protect the kidneys from 'bystander' damage caused by cancer therapies. The 'cell survival protein', called BCL-XL, was required in laboratory models to keep kidney cells alive and functioning during exposure to chemotherapy or radiotherapy. Kidney damage is a common side effect of these widely used cancer therapies, and the discovery has shed light on how this damage occurs at the molecular level. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 25, 2020 Category: Cancer & Oncology Source Type: news

New Findings on'Exceptional Responders' to Cancer Therapies New Findings on'Exceptional Responders' to Cancer Therapies
Why do a small percentage of patients with cancer show exceptional responses to cancer therapy? The answer may lie in their genetic makeup.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 23, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

‘This is a milestone’: Cincinnati Children’s, UC Health first to test cutting-edge cancer therapy
"Treating the first patient in this clinical trial is a milestone that many thought was still years ahead of us." (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 19, 2020 Category: American Health Authors: Liz Engel Source Type: news

Singapore scientists identify potential new biomarker to better personalize cancer therapy
(Duke-NUS Medical School) Testing for mutations in RNF43, a protein that affects key cancer cell-growth pathway Wnt, gives clinicians actionable insights to tailor treatments better. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2020 Category: Cancer & Oncology Source Type: news

Shining a light on the role of the genome's 'dark matter' in cancer development
(Duke-NUS Medical School) Innovative research by scientists at Duke-NUS Medical School has shed light on the mysterious role of long non-coding RNAs in the development of pancreatic cancer and suggests potential new targets for precision cancer therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2020 Category: Cancer & Oncology Source Type: news

Researcher receives $2.9 million for work improving effectiveness in lung cancer therapy
(Indiana University School of Medicine) An Indiana University Melvin and Bren Simon Comprehensive Cancer Center researcher has been awarded a five-year, $2.9 million grant from the National Cancer Institute to develop a drug that could make radiation therapy far more effective. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 11, 2020 Category: International Medicine & Public Health Source Type: news

Combining Eastern medicine with Western to improve cancer therapy
(University of Houston) A University of Houston pharmaceutical researcher is testing an ancient Chinese herbal medicine formula, Xiao-Chai-Hu Tang, first described in 280 A.D., to see if it can protect cancer patients on the chemotherapy drug Irinotecan from a deadly side effect: Severe-delayed-onset diarrhea. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 4, 2020 Category: International Medicine & Public Health Source Type: news

Mayo Clinic study finds 1 in 8 patients with cancer harbor inherited genetic mutations
(Mayo Clinic) PHOENIX, Ariz. ? Genetic testing can uncover inherited genetic mutations, and could individualize cancer therapies, improve survival, manage cancer in loved ones and push the boundaries of precision medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 2, 2020 Category: Cancer & Oncology Source Type: news

Mayo Clinic study finds 1 in 8 patients with cancer harbor inherited genetic mutations
PHOENIX, Ariz. ? Genetic testing can uncover inherited genetic mutations, and could individualize cancer therapies, improve survival, manage cancer in loved ones and push the boundaries of precision medicine. In a new study published in JAMA Oncology, scientists with Mayo Clinic's Center for Individualized Medicine conducted genetic testing in more than 3,000 patients who were diagnosed with cancer at Mayo [...] (Source: Mayo Clinic Arizona News)
Source: Mayo Clinic Arizona News - November 2, 2020 Category: Hospital Management Source Type: news

Childhood cancer therapies cost effective in sub-Saharan Africa
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2020 Category: Drugs & Pharmacology Source Type: news

Small study supports radiation before CAR-T therapy
A small, retrospective study suggests that radiation therapy may be administered...Read more on AuntMinnie.comRelated Reading: PET with Axumin boosts prostate cancer outcomes Single-session SBRT speeds treatment of lung metastases New radiotracer increases multiple myeloma survival ASTRO: Radiation can nix side effects of T-cell therapy UPenn gets $12M grant for new cancer therapy center (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 28, 2020 Category: Radiology Source Type: news

Cancer Therapy Affects Sexual Health in 87% of Patients Cancer Therapy Affects Sexual Health in 87% of Patients
Most cancer survivors say their oncologist has not asked about sexual health. Female patients are less likely to be asked and less likely to be counseled about it prior to therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 28, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Cancer Therapy Affects Sexual Health in Most Patients Cancer Therapy Affects Sexual Health in Most Patients
Most cancer survivors say their oncologist has not asked about sexual health. Female patients are less likely to be asked and less likely to be counseled about it prior to therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 28, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Targeted Therapy: What Are Targeted Antiangiogenic Cancer Therapies?
Title: Targeted Therapy: What Are Targeted Antiangiogenic Cancer Therapies?Category: MedicationsCreated: 10/26/2020 12:00:00 AMLast Editorial Review: 10/26/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 26, 2020 Category: Cancer & Oncology Source Type: news

23.10.20: Not intended for U.S. and UK Media
FDA approves FoundationOne®CDx as companion diagnostic for Vitrakvi™ (larotrectinib) to aid in identifying NTRK fusion-positive patientsThe companion diagnostic (CDx) approval is part of the global collaboration between Bayer and Foundation Medicine, Inc. for the development and commercialization of next-generation sequencing (NGS)-based companion diagnostics in oncology / Detection of genomic alterations that drive the growth and spread of the tumor can guide treatment decisions for cancer therapies, such as available biomarker driven therapies / FoundationOne®CDx analyzes substitutions, insertion and deleti...
Source: Bayer IR Newsfeed: Events - October 24, 2020 Category: Pharmaceuticals Source Type: news

How a Twitter hashtag provides insights for doctors and support for people with breast cancer
A UCLA-led review of nine years of social media posts with the hashtag #BCSM suggests that Twitter can be a useful resource  not only for patients, but also for physicians and researchers.The hashtag — an initialism for “breast cancer social media” — first appeared on Twitter in 2011. Created by two cancer survivors, it was used to curate a weekly informational chat for people with breast cancer. Dr. Deanna Attai became one of the group’s moderators a few weeks later.“We physicians have a lot to learn from the online patient communities,” said Attai, an assistant clinical prof...
Source: UCLA Newsroom: Health Sciences - October 22, 2020 Category: Universities & Medical Training Source Type: news

Clinical Drug Candidate SDX-7320 Offsets Hyperglycemia Caused by...
Preclinical data indicate that SDX-7320 inhibits tumor growth and counteracts treatment-induced metabolic dysfunction, a safety concern that can interrupt PI3K/Akt/mTOR cancer therapy and lead to...(PRWeb October 21, 2020)Read the full story at https://www.prweb.com/releases/clinical_drug_candidate_sdx_7320_offsets_hyperglycemia_caused_by_pi3k_akt_mtor_cancer_therapies_and_restores_insulin_sensitivity_syndevrx_s_preclinical_studies_show/prweb17481606.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 21, 2020 Category: Pharmaceuticals Source Type: news

M.D. Anderson Cancer Center launches investment fund for cancer therapies
The University of Texas M.D. Anderson Cancer Center, one of the nation's most prestigious oncology hospitals, has a new investment fund to support promising cancer therapies. An entity called The Focus Fund GP LLC launched the The Cancer Focus Fund LP in partnership with Houston-based M.D. Anderson, according to an Oct. 20 press release. The oncology-focused investment fund will focus on supporting the advancement of investigational cancer therapies from late preclinic al development through clinical… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 20, 2020 Category: Pharmaceuticals Authors: Chris Mathews Source Type: news

Focus Fund and MD Anderson launch investment fund to support promising investigational cancer therapies in early-stage clinical trials
(University of Texas M. D. Anderson Cancer Center) The Focus Fund GP, LLC, in partnership with The University of Texas MD Anderson Cancer Center, has launched Cancer Focus Fund, LP, an oncology-focused investment fund designed to support the advancement of compelling investigational cancer therapies from late preclinical development through Phase I and Phase Ib/II clinical trials. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 20, 2020 Category: Cancer & Oncology Source Type: news

Yale Cancer Answers: Advancing breast cancer treatment and awareness
Podcast host Dr. Anees Chagpar and Yale ’s Dr. Lajos Pusztai discuss Breast Cancer Awareness Month, and the current state of breast cancer therapies. (Source: Yale Science and Health News)
Source: Yale Science and Health News - October 19, 2020 Category: Universities & Medical Training Source Type: news

Targeted Protein Degradation in Inflammation and Cancer Therapy,...
In this free webinar, the featured speakers will discuss PROTAC technology and challenges in the field as well as opportunities and strategies for developing PROTACs in cancer and inflammation....(PRWeb October 19, 2020)Read the full story at https://www.prweb.com/releases/targeted_protein_degradation_in_inflammation_and_cancer_therapy_upcoming_webinar_hosted_by_xtalks/prweb17479617.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 19, 2020 Category: Pharmaceuticals Source Type: news

Scientists propose potential method for imaging-guided synergistic cancer therapy
(Chinese Academy of Sciences Headquarters) A joint research team led by Prof. WANG Hui and Prof. LIN Wenchu from the High Magnetic Field Laboratory of the Hefei Institutes of Physical Science developed a synthesis of metal-free multifunctional therapeutic reagents, called graphitic carbon nitride quantum dots embedded in carbon nanosheets (CNQD-CN), via a one-step hydrothermal treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 15, 2020 Category: Cancer & Oncology Source Type: news

Anticancer compounds for B cell cancer therapy targeting cellular stress response
(The Wistar Institute) Wistar and collaborators from the University of Notre Dame are developing anticancer compounds targeting a pathway of the endoplasmic reticulum (ER) stress response implicated in the development of multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and lymphoma. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 13, 2020 Category: Biology Source Type: news

Immuneel signs pact with Hospital Cl ínic de Barcelona to work on cancer therapy
The collaboration opens up opportunities for co-development of advanced assets to be deployed in Spain and India, said Immuneel in a press release. Immuneel acquired the exclusive rights to develop and commercialise autologous ARI-0001 – a CD19 Chimeric antigen receptor (CAR) T cell therapy, in India. (Source: The Economic Times)
Source: The Economic Times - October 13, 2020 Category: Consumer Health News Source Type: news

DDT COA #000117: Network/Function Assessment of Cancer Therapy- Disease Related Symptom Scale (NFKSI-DRS)
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 7, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

' Tread Lightly' on De-escalation of Breast Cancer Therapy'Tread Lightly' on De-escalation of Breast Cancer Therapy
Practice-changing data suggest de-escalation of treatment in breast cancer, but are they relevant to minority patients who are'grossly underrepresented'in clinical trials?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 6, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Personalized cancer therapy improves outcomes in advanced disease, says study
(University of California - San Diego) Patients receiving care for advanced cancer at Moores Cancer Center at UC San Diego Health were more likely to survive or experience a longer period without their disease progressing if they received personalized cancer therapy, report University of California San Diego School of Medicine researchers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 2, 2020 Category: Cancer & Oncology Source Type: news